GPR55 promotes migration and adhesion of colon cancer cells indicating a role in metastasis

British Journal of Pharmacology

Volumn 173, Issue 1, 2016, Pages 142-154

  Kargl, J ^a   Andersen, L ^a   Hasenohrl C ^a   Feuersinger, D ^a   Stancic A ^a   Fauland, A ^b   Magnes, C ^b   El Heliebi, A ^a   Lax, S ^c   Uranitsch, S ^d   Haybaeck, J ^a   Heinemann, A ^a   Schicho, R ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b JOANNEUM RESEARCH   (Austria)

^c General Hospital Graz West   (Austria)

^d Central Laboratory Hospital of the Brothers of St John of God   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; G PROTEIN COUPLED RECEPTOR 55; LYSOPHOSPHOLIPID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; UNCLASSIFIED DRUG; 4-(4-(3-HYDROXYPHENYL)-3-(4-METHYLPHENYL)-6-OXO-1H,4H,5H,6H-PYRROLO(3,4-C)PYRAZOL-5-YL)BENZOIC ACID; AZABICYCLO DERIVATIVE; BENZOIC ACID DERIVATIVE; CANNABIDIOL; G PROTEIN COUPLED RECEPTOR; GPR55 PROTEIN, HUMAN; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM HOMEOSTASIS; CALCIUM MOBILIZATION; CANCER CELL; CELL ADHESION; CELL MIGRATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CARCINOGENESIS; LIVER METASTASIS; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; COLON TUMOR; LIVER TUMOR; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; AZABICYCLO COMPOUNDS; BENZOATES; CANNABIDIOL; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; HUMANS; LIVER NEOPLASMS; LYSOPHOSPHOLIPIDS; MICE; NEOPLASM METASTASIS; RECEPTORS, G-PROTEIN-COUPLED; RNA, SMALL INTERFERING;

EID: 84952638802     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13345     Document Type: Article

References (51)

1. Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yoshioka T, Okano Y, et al,. (2011). Rho-kinase inhibitor upregulates migration by altering focal adhesion formation via the Akt pathway in colon cancer cells. Eur J Pharmacol 650: 145-150.
2. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al., (2013a). The Concise Guide to PHARMACOLOGY 2013/14: ion channels. Br J Pharmacol 170: 1459-1581.
3. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013b). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1607-1651.
4. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013c). The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
5. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013d). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
6. Anavi-Goffer S, Baillie G, Irving AJ, Gertsch J, Greig IR, Pertwee RG, et al., (2012). Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J Biol Chem 287: 91-104.
7. Andradas C, Caffarel MM, Pérez-Gõmez E, Salazar M, Lorente M, Velasco G, et al., (2011). The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30: 245-252.
8. Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, et al., (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90: 925-934.
9. Balenga NA, Aflaki E, Kargl J, Platzer W, Schröder R, Blättermann S, et al., (2011). GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 21: 1452-1469.
10. Billah MM, Lapetina EG, (1982). Formation of lysophosphatidylinositol in platelets stimulated with thrombin or ionophore A23187. J Biol Chem 257: 5196-5200.
11. Davies SP, Reddy H, Caivano M, Cohen P, (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
12. Dorsam RT, Gutkind JS, (2007). G-protein-coupled receptors and cancer. Nat Rev Cancer 7: 79-94.
13. Fauland A, Köfeler H, Trötzmüller M, Knopf A, Hartler J, Eberl A, et al., (2011). A comprehensive method for lipid profiling by liquid chromatography-ion cyclotron resonance mass spectrometry. J Lipid Res 52: 2314-2322.
14. Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, et al., (2010). A role for L-alpha-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160: 762-771.
15. Fredriksson R, Lagerström MC, Lundin LG, Schiöth HB, (2003). The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63: 1256-1272.
16. Gladbach A, van Eersel J, Bi M, Ke YD, Ittner LM, (2014). ERK inhibition with PD184161 mitigates brain damage in a mouse model of stroke. J Neural Transm 121: 543-547.
17. Hanahan D, Weinberg RA, (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
18. 2+ signaling and NFAT activation. FASEB J 23: 183-193.
19. Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, Irving A, et al., (2011). Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 25: 1835-1848.
20. Huang L, Ramirez JC, Frampton GA, Golden LE, Quinn MA, Pae HY, et al., (2011). Anandamide exerts its antiproliferative actions on cholangiocarcinoma by activation of the GPR55 receptor. Lab Invest 91: 1007-1017.
21. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
22. Juneja J, Casey PJ, (2009). Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol 158: 32-40.
23. 1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem 287: 44234-44248.
24. Kargl J, Brown AJ, Andersen L, Dorn G, Schicho R, Waldhoer M, et al., (2013a). A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther 346: 54-66.
25. Kargl J, Haybaeck J, Stančic A, Andersen L, Marsche G, Heinemann A, et al., (2013b). O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms. J Mol Med (Berl) 91: 449-458.
26. Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, et al., (2013). Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52: 9456-9469.
27. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K, (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704.
28. Mancini M, Toker A, (2009). NFAT proteins: emerging roles in cancer progression. Nat Rev Cancer 9: 810-820.
29. 2+-independent pathways for release of arachidonic acid from phosphatidylinositol in endothelial cells. J Biol Chem 262: 13086-13092.
30. Matyash V, Liebisch G, Kurzchalia TV, Shevchenko A, Schwudke D, (2008). Lipid extraction by methyl-tert-butyl ether for high-throughput lipidomics. J Lipid Res 49: 1137-1146.
31. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
32. Monet M, Gkika D, Lehen'kyi V, Pourtier A, Vanden Abeele F, Bidaux G, et al., (2009). Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 1793: 528-539.
33. Nabissi M, Morelli MB, Santoni M, Santoni G, (2013). Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34: 48-57.
34. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T, (2009). 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145: 13-20.
35. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-106.
36. Pérez-Gõmez E, Andradas C, Flores JM, Quintanilla M, Paramio JM, Guzmán M, et al., (2012). The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene 32: 2534-2542.
37. Piñeiro R, Maffucci T, Falasca M, (2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30: 142-152.
38. Prevarskaya N, Skryma R, Shuba Y, (2011). Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer 11: 609-618.
39. Rajput A, Dominguez San Martin I, Rose R, Beko A, Levea C, Sharratt E, et al., (2008). Characterization of HCT116 human colon cancer cells in an orthotopic model. J Surg Res 147: 276-281.
40. Ramer R, Bublitz K, Freimuth N, Merkord J, Rohde H, Haustein M, et al., (2012). Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 26: 1535-1548.
41. Ross RA, (2011). L-α-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci 32: 265-269.
42. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, et al., (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
43. Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, et al., (2011). Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 103: 1018-1036.
44. Shen Z, Wu M, Elson P, Kennedy AW, Belinson J, Casey G, et al., (2001). Fatty acid composition of lysophosphatidic acid and lysophosphatidylinositol in plasma from patients with ovarian cancer and other gynecological diseases. Gynecol Oncol 83: 25-30.
45. Smith DM, Waite M, (1992). Phosphatidylinositol hydrolysis by phospholipase A2 and C activities in human peripheral blood neutrophils. J Leukoc Biol 52: 670-678.
46. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, Hughes JP, et al., (2008). The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 225-236.
47. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D, (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144: 1032-1036.
48. van Nieuw Amerongen GP, Vermeer MA, van Hinsbergh VW, (2000). Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 20: E127-E133.
49. Wang L, Xue L, Yan H, Li J, Lu Y, (2010). Effects of ROCK inhibitor, Y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep 37: 1971-1917.
50. Wiggins H, Rappoport J, (2010). An agarose spot assay for chemotactic invasion. Biotechniques 48: 121-124.
51. Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE, (2010). Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160: 1583-1594.